Editorial: Perspectives of Pharmacokinetics and Metabolism in Drug Design

Hsieh, Yunsheng
July 2009
Current Pharmaceutical Design;7/1/2009, Vol. 15 Issue 19, p2169
Academic Journal
The article discusses various reports published within the issue, including one by W. Tang and A. Y. H. Lu on drug metabolism and pharmacokinetics (DMPK) strategies, one by J. Wang on in vitro approaches for assessing risk associated with new chemicals and another one by J. Fang on the developments of prodrugs.


Related Articles

  • Subject Index To Volume 2. Bentham, S. // Current Drug Metabolism;Feb2002, Vol. 3 Issue 1, p117 

    Presents subject index to Volume 2 of the journal 'Current Drug Metabolism.' Anthracyclines; Bestastatin; Brain cytochrome P450; Brain microdialysis technique to study drug transport; Chimeragenesis; Chiral medicinal products; CYP1A1 gene.

  • Metabolism of fibric acid derivatives. Spence, J.D. // Clinical Pharmacokinetics;1998, Vol. 34 Issue 5, p419 

    Presents an apology from the editorial staff of 'Clinical Pharmacokinetics' concerning the publishing of an article about the clinical pharmacokinetics of fibric acid derivatives. Metabolism by cytochrome P450 (CYP) 3A4; Information on the involvement of enzymes in the metabolism process;...

  • Drugs in nails: physiology, pharmacokinetics and forensic toxicology. Palmeri, A.; Pichini, S.; Pacifici, R.; Zuccaro, P.; Lopez, A. // Clinical Pharmacokinetics;2000, Vol. 38 Issue 2, p95 

    In recent years, drug analysis in keratinised matrices, such as hair and nails, has received considerable attention because of several advantages over drug testing methodologies employing body fluids, such as urine or serum. For example, keratinic matrices, such as finger- and toenails, can...

  • Metabolism and pharmacokinetics of oxazaphosphorines. Boddy, A.V.; Murray Yule, S.; Yule, S M // Clinical Pharmacokinetics;2000, Vol. 38 Issue 4, p291 

    The 2 most commonly used oxazaphosphorines are cyclophosphamide and ifosfamide, although other bifunctional mustard analogues continue to be investigated. The pharmacology of these agents is determined by their metabolism, since the parent drug is relatively inactive. For cyclophosphamide,...

  • Induction of Drug Metabolising Enzymes. Fuhr, Uwe // Clinical Pharmacokinetics;2000, Vol. 38 Issue 6, p493 

    Currently, 5 different main mechanisms of induction are distinguished for drug-metabolising enzymes. The ethanol type of induction is mediated by ligand stabilisation of the enzyme, but the others appear to be mediated by intracellular 'receptors'. These are the aryl hydrocarbon (Ah) receptor,...

  • Pharmacokinetics of Fluticasone Propionate Inhaled via the Diskhaler and Diskus Powder Devices in Patients with Mild-to-Moderate Asthma. Falcoz, C.; Horton, J.; Mackie, A.E.; Harding, S.M.; Daley-Yates, P.T. // Clinical Pharmacokinetics;2000 Supplement, Vol. 39 Issue 6, p31 

    Objective: The aim of these studies was to compare the pharmacokinetics of inhaled fluticasone propionate (FP) after repeated administration via the Diskus or Diskhaler dry powder inhalers (DPIs) to patients with mild-to-moderate asthma. Methods: Both studies evaluated the pharmacokinetics of...

  • Cimetidine Impairs Elimination of Chlordiazepoxide (Librium) in Man. Desmond, Paul V.; Patwardhan, Rashmi V.; Schenker, Steven; Speeg Jr., K. V. // Annals of Internal Medicine;Aug80, Vol. 93 Issue 2, p266 

    Presents a study which studied chlordiazepoxide (Librium) disposition and elimination in patients who underwent cimetidine therapy. Interaction of cimetidine and drug metabolism; Time of course of drug inhibition; Effects of cimetidine and chlordiazepoxide.

  • ERRATUM.  // Drug Metabolism Letters;Aug2011, Vol. 5 Issue 3, p231 

    A correction to the article "Comparative Pharmacokinetics and Metabolism Studies in Lean and Diet-Induced Obese Mice, An Animal Efficacy Model for 11-Hydroxysteroid Dehydrogenase Type 1 (11-HSD1) Inhibitors," by Mengmeng Wang et al. that was published in issue 01 of 2011 is presented.

  • Ian Baines MSB.  // Biologist;Apr/May2013, Vol. 60 Issue 2, p43 

    The article presents the author's views on various issues which include his job as drug metabolism and pharmacokinetics senior scientist at GlaxoSmithKline, why he loves chemistry and biology, and the role of drug metabolism and pharmacokinetics research to advance personalised medicines.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics